Clinuvel Pharmaceuticals (CUVL) vs Prelude Therapeutics (PRLD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Prelude Therapeutics (PRLD) has outperformed Clinuvel Pharmaceuticals (CUVL) over the past year, gaining 173.2% versus a loss of 31.6%. Over five years, PRLD leads with a -76.4% price change compared with -81.6% for CUVL. Prelude Therapeutics is the larger company by market cap ($309.6 million vs $282.7 million), about 1.1 times the size.
Clinuvel Pharmaceuticals pays a dividend yielding 0.89%, while Prelude Therapeutics does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUVL | PRLD |
|---|---|---|
| Share price | $5.60 | $3.88 |
| Market cap | $282.73M | $309.64M |
| 1-day change | -3.45% | +1.31% |
| YTD return | -33.96% | +33.79% |
| 1-year return | -31.62% | +173.24% |
| 5-year return | -81.60% | -76.45% |
| P/E ratio (TTM) | 12.44 | — |
| EPS (TTM) | $0.45 | $-0.73 |
| Dividend yield | 0.89% | 0.00% |
| Annual dividend | $0.05 | $0.00 |
| 52-week high | $8.92 | $6.83 |
| 52-week low | $5.53 | $1.15 |
| Distance from 52-week high | -37.22% | -43.19% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +137.11% |
| Average volume | 13.01K | 479.23K |
| Shares outstanding | 50.49M | 65.08M |
| Employees | — | 79 |
| Sector | Miscellaneous | Health Care |
| Industry | Miscellaneous | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRLD has outperformed CUVL by 204.9 percentage points over the past year.
- The two companies sit in different sectors: Clinuvel Pharmaceuticals in Miscellaneous and Prelude Therapeutics in Health Care.
About Clinuvel Pharmaceuticals
CUVL stock →Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).
Miscellaneous · Miscellaneous
About Prelude Therapeutics
PRLD stock →Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.
Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees
CUVL vs PRLD FAQ
Which is bigger, Clinuvel Pharmaceuticals or Prelude Therapeutics?
Prelude Therapeutics (PRLD) is larger, with a market capitalization of $309.64M compared with $282.73M for Clinuvel Pharmaceuticals (CUVL).
Which stock has performed better over the past year, CUVL or PRLD?
PRLD returned +173.24% over the past 12 months, compared with -31.62% for CUVL (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Clinuvel Pharmaceuticals or Prelude Therapeutics?
Clinuvel Pharmaceuticals pays a dividend yielding 0.89%, while Prelude Therapeutics does not currently pay a regular dividend.
Are Clinuvel Pharmaceuticals and Prelude Therapeutics in the same industry?
No. Clinuvel Pharmaceuticals is in the Miscellaneous sector, while Prelude Therapeutics is in Health Care.